Welcome to our dedicated page for Jazz Pharmaceuticals plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jazz Pharmaceuticals plc filings document material events for an Ireland-domiciled biopharmaceutical issuer with Nasdaq-listed ordinary shares. Recent 8-K reports furnish quarterly and annual financial results, guidance, corporate presentations and product-level commentary for Xywav, Epidiolex, Modeyso and oncology launches.
The company’s filings also record clinical and regulatory disclosures for Ziihera (zanidatamab-hrii) and the HERIZON-GEA-01 program, board and committee changes, standard director compensation and indemnification arrangements, and settlement agreements involving patent and related commercial disputes. These records tie Jazz’s capital-market disclosures to its neuroscience and oncology portfolio, governance structure and material business events.
RIEDEL NORBERT G reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals plc director Norbert G. Riedel received a grant of 1,605 restricted stock units on August 5, 2026 under the 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each unit represents a contingent right to one ordinary share and will vest in full on July 23, 2027, subject to continuous service and other conditions. Following the award, 8,629 ordinary shares were reported as beneficially owned by the NORBERT G. RIEDEL 2023 TRUST, and a separate indirect holding entry shows 10,630 ordinary shares held by trust.
COZADD BRUCE C reported acquisition or exercise transactions in this Form 4 filing.
Bruce C. Cozadd, a director of Jazz Pharmaceuticals plc, reported an equity compensation grant of 1,605 restricted stock units, each representing one ordinary share. The award carries a reported price per share of $0.00 and will vest in full on July 23, 2027, subject to continuous service and other conditions. Following this grant, Cozadd directly holds 362,287 ordinary shares of Jazz Pharmaceuticals.
FMR LLC and Abigail P. Johnson report beneficial ownership of common stock of Jazz Pharmaceuticals plc. FMR LLC reports beneficial ownership of 4,675,458.82 shares of common stock, representing 7.4% of the class, with 4,618,210.03 shares having sole voting power and 4,675,458.82 shares subject to sole dispositive power. Abigail P. Johnson reports beneficial ownership of 4,675,458.82 shares with sole dispositive power and no shares with sole or shared voting power, corresponding to 7.4% of the class. One or more other persons have rights to receive dividends or sale proceeds from these securities, but no such person has an interest exceeding five percent of Jazz Pharmaceuticals plc common stock.
Jazz Pharmaceuticals director Bruce C. Cozadd sold 6,000 Ordinary Shares on August 3, 2026 at $252.98 per share in a sale described as an open market or private transaction. The sale occurred automatically under a Rule 10b5-1 trading plan adopted on November 26, 2025, and does not represent a discretionary trade. Following this transaction, he directly holds 360,682 shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals plc reporting person Bruce Cozadd plans to sell 6,000 shares of common stock through Merrill Lynch on or after August 3, 2026 on NASDAQ. The shares relate to stock options dated February 28, 2019.
Cozadd also reports sales of 6,000 common shares in each of the prior three months: on May 1, 2026 for $1,213,980, on June 1, 2026 for $1,410,720, and on July 1, 2026 for $1,442,820.
Jazz Pharmaceuticals reported second-quarter 2026 revenues of $1,208.3 million, up from $1,045.7 million a year earlier, and net income of $192.8 million versus a net loss of $718.5 million. For the first six months, revenues were $2,277.2 million and net income was $485.9 million, compared with a loss of $811.0 million in the prior-year period. Results reflect $77.0 million of acquired in-process R&D versus $905.4 million last year and a $122.8 million gain on sale of a priority review voucher.
Product sales reached $1,156.1 million, led by Xywav at $471.2 million, Epidiolex/Epidyolex at $292.1 million, and oncology medicines at $362.3 million, including Zepzelca, Rylaze/Enrylaze, Defitelio, Modeyso and Ziihera. U.S. revenues were $1,077.9 million. Exiting the quarter, there were approximately 17,125 active Xywav patients, including about 11,275 with narcolepsy and 5,850 with idiopathic hypersomnia.
Jazz generated $823.9 million of operating cash flow in the first half, ending June 30, 2026 with $1,619.8 million in cash and cash equivalents and $580.0 million in investments. Total debt declined to $4,351.4 million from $5,358.3 million after repaying the $1.0 billion 2026 exchangeable notes, issuing 1.89 million shares for the conversion premium, while the $1.0 billion 2030 notes became exchangeable and were classified as current. During the quarter, Jazz paid $56.0 million upfront to AbCellera for a multispecific antibody collaboration and $21.0 million to acquire remaining rights to JZP898 from Werewolf, both expensed as acquired in-process R&D.
Jazz Pharmaceuticals reported record second quarter 2026 revenues of $1,208.3 million, up 16% year-over-year, driven by growth in Xywav, Epidiolex/Epidyolex, Zepzelca and contributions from Modeyso and Ziihera. GAAP net income was $192.8 million, or $2.78 per diluted share, and non-GAAP adjusted EPS was $5.71.
The company generated $823.9 million of cash from operations in the first half of 2026 and held $2.2 billion in cash, cash equivalents and investments against $4.4 billion of long-term debt, after repaying $1.0 billion of 2.00% exchangeable senior notes due 2026. Full-year 2026 total revenue guidance was raised to $4,600–$4,750 million. Jazz highlighted regulatory milestones, including FDA Priority Review for zanidatamab in first-line HER2+ gastroesophageal adenocarcinoma with an August 25, 2026 PDUFA date and Breakthrough Therapy designation in HER2-positive colorectal cancer.
Jazz Pharmaceuticals plc held its 2026 annual general meeting in Dublin, where shareholders voted on six proposals. Holders of 57,836,785 of 62,817,628 ordinary shares entitled to vote were present in person or by proxy.
Shareholders elected three directors to serve until the 2029 annual meeting, approved KPMG, Dublin as independent auditors and authorized the audit committee to set their remuneration, and gave non-binding approval of named executive officer compensation. They also approved board authority under Irish law to allot ordinary shares, including to issue shares for cash without first offering them to existing shareholders under statutory pre-emption rights. The contingent adjournment proposal was not put to a vote.
Jazz Pharmaceuticals plc director Bruce C. Cozadd reported an open-market sale of 6,000 Ordinary Shares of JAZZ on July 1, 2026 at an average price of $240.47 per share. The filing shows that Cozadd continues to directly hold 366,682 Ordinary Shares after this transaction.
According to the disclosure, the trade was executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025, meaning the timing was set in advance and was not a discretionary decision by the reporting person.